Lipocine Inc.
US ˙ NasdaqCM ˙ US53630X2036

Introduction

This page provides a comprehensive analysis of the known insider trading history of Patel Mahesh V.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Patel Mahesh V. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:LPCN / Lipocine Inc. CEO and President, Director 112,311
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Patel Mahesh V.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases LPCN / Lipocine Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in LPCN / Lipocine Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-05-25 LPCN Patel Mahesh V. 8,706 5.0300 8,706 5.0300 43,791 365 6.8900 16,193 36.98
2023-03-24 LPCN Patel Mahesh V. 150,000 0.3200 8,824 5.4400 48,000
2023-03-17 LPCN Patel Mahesh V. 50,000 0.3300 2,941 5.6100 16,500
2022-11-14 LPCN Patel Mahesh V. 75,000 0.3900 4,412 6.6300 29,250
2022-09-27 LPCN Patel Mahesh V. 100,000 0.4100 5,882 6.9700 41,000
2022-05-16 LPCN Patel Mahesh V. 50,000 0.7699 2,941 13.0883 38,495
2021-11-18 LPCN Patel Mahesh V. 25,000 1.0900 1,471 18.5300 27,250
2019-12-31 LPCN Patel Mahesh V. 40,000 0.3835 2,353 6.5195 15,340
2019-12-10 LPCN Patel Mahesh V. 25,000 0.3990 1,471 6.7830 9,975
2019-11-26 LPCN Patel Mahesh V. 1,272 0.4265 75 7.2505 543
2019-11-26 LPCN Patel Mahesh V. 700 0.4266 41 7.2522 299
2019-11-26 LPCN Patel Mahesh V. 1,100 0.4270 65 7.2590 470
2019-11-26 LPCN Patel Mahesh V. 21,928 0.4280 1,290 7.2760 9,385
2019-11-18 LPCN Patel Mahesh V. 4,931 0.3999 290 6.7983 1,972
2019-11-18 LPCN Patel Mahesh V. 40,259 0.4000 2,368 6.8000 16,104
2019-11-18 LPCN Patel Mahesh V. 4,810 0.4198 283 7.1366 2,019
2015-09-30 LPCN Patel Mahesh V. 2,000 12.0000 118 204.0000 24,000
2015-09-30 LPCN Patel Mahesh V. 700 11.6799 41 198.5583 8,176
2015-09-30 LPCN Patel Mahesh V. 1,300 11.6760 76 198.4920 15,179
2014-11-25 LPCN Patel Mahesh V. 2,000 5.1000 118 86.7000 10,200
2014-11-24 LPCN Patel Mahesh V. 2,000 5.4500 118 92.6500 10,900
2014-11-14 LPCN Patel Mahesh V. 1,900 5.0600 112 86.0200 9,614
2014-11-14 LPCN Patel Mahesh V. 100 5.0599 6 86.0183 506
2014-11-13 LPCN Patel Mahesh V. 2,000 5.0520 118 85.8840 10,104

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LPCN / Lipocine Inc. Insider Trades
Insider Sales LPCN / Lipocine Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in LPCN / Lipocine Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LPCN / Lipocine Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Patel Mahesh V. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-03-12 2024-03-08 4 LPCN Lipocine Inc.
Common Stock
A - Award 4,893 112,311 4.56
2023-05-25 2023-05-25 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 8,706 107,418 8.82 5.03 43,791 540,313
2023-03-24 2023-03-24 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 150,000 1,678,090 9.82 0.32 48,000 536,989
2023-03-17 2023-03-17 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 50,000 1,528,090 3.38 0.33 16,500 504,270
2022-11-14 2022-11-14 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 75,000 1,478,090 5.35 0.39 29,250 576,455
2022-09-27 2022-09-27 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 100,000 1,403,090 7.67 0.41 41,000 575,267
2022-05-16 2022-05-16 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 50,000 1,303,090 3.99 0.77 38,495 1,003,249
2022-01-03 2022-01-03 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 287,500 287,500 1.09 313,375 313,375
2021-12-08 2021-12-07 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 125,000 125,000 1.12 140,000 140,000
2021-11-18 2021-11-18 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 25,000 1,253,090 2.04 1.09 27,250 1,365,868
2021-01-04 2021-01-04 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 275,000 275,000 1.43 393,250 393,250
2020-12-29 2020-12-28 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
J - Other -275,000 100,000 -73.33
2020-12-17 2020-12-16 4 LPCN Lipocine Inc.
Restricted Stock Unit
M - Exercise 45,000 45,000
2020-12-17 2020-12-16 4 LPCN Lipocine Inc.
Common Stock
S - Sale X -15,000 1,228,090 -1.21 1.35 -20,250 1,657,922
2020-12-17 2020-12-16 4 LPCN Lipocine Inc.
Common Stock
M - Exercise 45,000 1,243,090 3.76
2020-12-17 2020-12-15 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 375,000 375,000 1.37 513,750 513,750
2020-12-08 2020-12-05 4 LPCN Lipocine Inc.
Restricted Stock Unit
M - Exercise -122,978 122,978 -50.00
2020-12-08 2020-12-05 4 LPCN Lipocine Inc.
Common Stock
M - Exercise 122,978 1,198,090 11.44
2020-12-08 2020-12-04 4 LPCN Lipocine Inc.
Restricted Stock Unit
M - Exercise -145,000 145,000 -50.00
2020-12-08 2020-12-04 4 LPCN Lipocine Inc.
Common Stock
S - Sale X -43,500 1,075,112 -3.89 1.57 -68,134 1,683,948
2020-12-08 2020-12-04 4 LPCN Lipocine Inc.
Common Stock
M - Exercise 145,000 1,118,612 14.89
2020-01-28 2020-01-28 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 300,000 300,000 0.46 137,400 137,400
2020-01-02 2019-12-31 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 40,000 973,612 4.28 0.38 15,340 373,380
2019-12-10 2019-12-10 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 25,000 933,612 2.75 0.40 9,975 372,511
2019-12-06 2019-12-05 4 LPCN Lipocine Inc.
Restricted Stock Unit
A - Award 122,978 122,978
2019-12-06 2019-12-04 4 LPCN Lipocine Inc.
Restricted Stock Unit
M - Exercise -145,000 145,000 -50.00
2019-12-06 2019-12-04 4 LPCN Lipocine Inc.
Common Stock
S - Sale X -43,500 908,612 -4.57 0.41 -17,835 372,531
2019-12-06 2019-12-04 4 LPCN Lipocine Inc.
Common Stock
M - Exercise 145,000 952,112 17.97
2019-11-26 2019-11-26 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 21,928 807,112 2.79 0.43 9,385 345,444
2019-11-26 2019-11-26 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 1,100 785,184 0.14 0.43 470 335,274
2019-11-26 2019-11-26 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 700 784,084 0.09 0.43 299 334,490
2019-11-26 2019-11-26 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 1,272 783,384 0.16 0.43 543 334,113
2019-11-18 2019-11-18 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 4,810 782,112 0.62 0.42 2,019 328,331
2019-11-18 2019-11-18 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 40,259 777,302 5.46 0.40 16,104 310,921
2019-11-18 2019-11-18 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 4,931 737,043 0.67 0.40 1,972 294,743
2019-05-28 2019-05-24 4 LPCN Lipocine Inc.
Common Stock
A - Award 2,500 732,112 0.34 1.64 4,100 1,200,664
2019-05-28 2019-05-24 4 LPCN Lipocine Inc.
Common Stock
A - Award 473 729,612 0.06 1.60 757 1,167,379
2019-05-28 2019-05-24 4 LPCN Lipocine Inc.
Common Stock
A - Award 2,500 729,139 0.34 1.59 3,975 1,159,331
2019-05-28 2019-05-24 4 LPCN Lipocine Inc.
Common Stock
A - Award 4,527 726,639 0.63 1.58 7,153 1,148,090
2018-12-06 2018-12-04 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 150,000 150,000 1.46 219,000 219,000
2018-12-06 2018-12-04 4 LPCN Lipocine Inc.
Restricted stock unit
A - Award 290,000 290,000
2018-01-02 2017-12-29 4 LPCN Lipocine Inc.
Restricted Stock Unit
M - Exercise -15,000 45,000 -25.00
2018-01-02 2017-12-29 4 LPCN Lipocine Inc.
Common stock
S - Sale X -6,000 722,112 -0.82 3.48 -20,867 2,511,361
2018-01-02 2017-12-29 4 LPCN Lipocine Inc.
Common Stock
M - Exercise 15,000 728,112 2.10
2017-12-06 2017-12-06 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 150,000 150,000 3.52 528,000 528,000
2017-01-30 2017-01-26 4 LPCN Lipocine Inc.
Restricted Stock Unit
A - Award 60,000 60,000
2016-12-08 2016-12-07 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 140,000 140,000 3.61 505,400 505,400
2016-01-07 2016-01-05 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 140,000 140,000 12.92 1,808,800 1,808,800
2015-10-02 2015-09-30 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 1,300 887,632 0.15 11.68 15,179 10,363,991
2015-10-02 2015-09-30 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 700 886,332 0.08 11.68 8,176 10,352,269
2015-10-02 2015-09-30 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 2,000 885,632 0.23 12.00 24,000 10,627,584
2014-11-25 2014-11-25 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 2,000 885,632 0.23 5.10 10,200 4,516,723
2014-11-24 2014-11-24 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 2,000 883,632 0.23 5.45 10,900 4,815,794
2014-11-14 2014-11-14 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 100 881,632 0.01 5.06 506 4,460,970
2014-11-14 2014-11-14 4 LPCN Lipocine Inc.
Common Stock
P - Purchase 1,900 881,532 0.22 5.06 9,614 4,460,552
2014-11-13 2014-11-13 4 LPCN Lipocine Inc.
Cmmon Stock
P - Purchase 2,000 879,632 0.23 5.05 10,104 4,443,901
2014-08-15 2014-08-14 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 105,116 105,116
2013-12-11 2013-12-10 4 LPCN Lipocine Inc.
Restricted Stock Unit
A - Award 10,000 10,000
2013-12-11 2013-12-10 4 LPCN Lipocine Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2013-08-02 3 MBARD Lipocine Inc.
Common Stock
688,920
2013-08-02 3 MBARD Lipocine Inc.
Common Stock
2,192
2013-08-02 3 MBARD Lipocine Inc.
Common Stock
186,520
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)